

Perrigo®



Third Quarter Calendar Year 2018 Financial Results
November 8, 2018

Forward Looking Statements

Certain statements in this presentation are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "forecast," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the timing, amount and cost of any share repurchases; future impairment charges; the success of management transition; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressure from customers and consumers; potential third-party claims and litigation, including litigation relating to the Company's restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; resolution of uncertain tax positions; the impact of tax reform legislation and healthcare policy; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions and the success of such transactions, and the Company's ability to realize the desired benefits thereof; and the Company's ability to execute and achieve the desired benefits of announced cost-reduction efforts and strategic initiatives and other Statements regarding the separation of the RX business, including the expected benefits, anticipated timing, form of any such separation and whether the separation ultimately occurs, are all subject to various risks and uncertainties, including future financial and operating results, our ability to separate the business, the effect of existing interdependencies with our manufacturing and shared service operations, and the tax consequences of the planned separation to the Company or its shareholders. In addition, the Company may identify new, or be unable to remediate previously identified, material weaknesses in its internal control over financial reporting. Furthermore, the Company may incur additional tax liabilities in respect of 2016 and prior years or be found to have breached certain provisions of Irish company law in connection with the Company's restatement of previously-filed financial statements, which may result in additional expenses and penalties. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2017, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Non-GAAP Measures

This presentation contains non-GAAP measures. The reconciliation of those measures to the most comparable GAAP measures is included at the end of this presentation. A copy of this presentation, including the reconciliations, is available on the Company's website at www.perrigo.com.



**Bradley Joseph,
VP Investor Relations and
Corporate Communications**

AGENDA

- **Third Quarter Financial Results**
- **Balance Sheet Strength**
- **Updated Guidance**
- **Introduction to Murray S. Kessler**
- **CEO Commentary**
- **Q&A**



**Ron Winowiecki,
CFO**

Third Quarter 2018 Financial Results (1)

Q3 Net Sales in Worldwide Consumer-Facing Businesses Grew 2% YoY(2)

Consolidated Q3 Results

Net Sales	\$1.1B
Adjusted Operating Income	\$208M
Adjusted EPS	\$1.09
Cash From Operations	\$144M



Q3 and YTD 2018 Highlights

CHC Americas

- Q3: Net sales grew ~3% YoY, excluding animal health
- YTD: Net sales grew ~3% YoY, excluding animal health

CHC International

- Q3: Adjusted operating margin increased 230 bps to ~19%
- YTD: Adjusted operating margin ~17%

RX

- Q3: R&D spend ~11% to net sales
- YTD: R&D ~8% to net sales

Adjusted Cash From Operations

- Q3: Conversion to adjusted net income of ~96%
- YTD: Adjusted conversion to adjusted net income of ~90%

Consolidated – Q3 2018 Financial Information



(\$ in millions, except per share amounts)	Q3 2018 Reported	Q3 2018 Adjusted ⁽¹⁾	Q3 2017 Reported	Reported Change YoY%	Primary Non-GAAP Adjustments
Net Sales	\$1,133	N/A	\$1,231	(8)%	
Gross Profit	\$425	\$477	\$498	(15)%	• Acquisition related amortization expenses
R&D Expense	44	43	38	14%	• Acquisition related amortization expenses
Distribution, Selling & Administrative Expense (DSG&A)	263	226	288	(9)%	• Acquisition related amortization expenses; gain/loss on divestitures; unusual litigation; separation and reorganization expenses; acquisition-related charges and contingent consideration adjustments
Impairments, Restructuring, Other Operating Income (Loss)	\$240	\$0	\$9	NM	• Restructuring charges; acquisition-related charges; contingent consideration adjustments and impairment charges
Operating Income	\$(122)	\$208	\$162	NM	• Acquisition related amortization expenses; gain/loss on divestitures; unusual litigation; separation and reorganization expenses; acquisition-related charges; contingent consideration adjustments; restructuring charges and impairment charges
Change in Financial Asset, Interest & Other Expense and Loss on Extinguishment of Debt	(43)	29	34	NM	• Change in financial assets; gain/loss on divestitures and losses on investment securities
Effective Tax Rate	14.5%	16.2%	65.5%	NM	
Net Income (Loss)	\$(68)	\$150	\$45	NM	
Diluted Earnings (Loss) per Share	\$(0.49)	\$1.09	\$0.31	NM	

(1) See attached Appendix for reconciliation of Adjusted (Non-GAAP) to Reported (GAAP) amounts

CHC Americas Segment As Adjusted⁽¹⁾ – Q3 2018

Year-Over-Year Performance

(in millions)




Q3 2018 Highlights

- **NET SALES**
 - Grew 3%, excluding the animal health business, driven by the smoking cessation, infant formula and dermatological categories
 - New product sales were \$13 million
- **MARGIN**
 - Adjusted operating margin of ~19%
 - Adjusted gross margin of ~33% driven by lower net sales in the animal health business and operating inefficiencies



CHC International Segment As Adjusted⁽¹⁾ – Q3 2018

Year-Over-Year Performance




Q3 2018 Highlights

- **NET SALES**
 - Increased ~1%, on an organic constant currency basis, driven by the analgesic, anti-parasite and personal care categories
 - New product sales were ~ \$19 million
- **MARGIN**
 - Adjusted gross margin improved 120 bps driven by improvement initiatives including new product margin contributions
 - Adjusted operating margin improved 230 bps to ~19% due primarily to adjusted gross margin improvement and operating leverage

RX Pharmaceuticals Segment As Adjusted⁽¹⁾ – Q3 2018

Year-Over-Year Performance

(in millions)



Q3 2018 Highlights

- **NET SALES**
 - Lower due to absence of new products, price erosion in authorized generic products and customer service challenges resulting in lower sales volumes
- **MARGIN**
 - Adjusted gross margin ~52% driven by less favorable product mix
 - R&D investments represented ~11% of net sales, ~600 bps higher versus last year
 - Adjusted operating margin of 32% resulted from adjusted gross margin flow through and increased R&D investments



Balance Sheet Strength



\$444M

Total Cash as
of 9/30/2018



~\$3.3B

Total Debt as
of 9/30/2018



Committed to investment
grade status



Repurchased ~1.8 million
shares in the third quarter



New \$1B share repurchase
authorization

Updated Guidance Driven Primarily by Rx

Consolidated Calendar Year 2018 Guidance⁽¹⁾

	Guidance Provided on 11/8/2018	Guidance Provided on 8/9/2018
Net Sales	~\$4.72B	\$4.8B – \$4.9B
Adjusted Diluted EPS	~\$4.45 – \$4.65	\$4.75 – \$4.95

Strong Leader With Proven Track Record

Murray S. Kessler, President & CEO



Significant Experience

- More than 30 years of experience in consumer products, including notable leadership positions at Lorillard, UST, Inc., Vlasic Foods International, Campbell Soup Company and The Clorox Company

Strategic Innovator

- As a leading innovator in the industry, Mr. Kessler led Lorillard and UST's expansion into new and emerging categories during his tenure

Established Track Record:

- Created \$22B in market capitalization combined in the last two CEO positions

CEO Commentary

Perrigo®




Q&A

Perrigo®



U.S. Store Brand Growth Continues to Outpace National Brand



APPENDIX

TABLE I
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP
MEASURES
SELECTED CONSOLIDATED INFORMATION
(in millions, except per share amounts)
(unaudited)

Three Months Ended September 29, 2018

Consolidated	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Restructuring, Impairment Charges, and Other Operating Income	Operating Income (Loss)	Interest, Other, and Change in financial assets	Income Tax Expense (Benefit)	Net Income (Loss)	Diluted Earnings (Loss) per Share
Reported	\$ 1,133.1	\$ 424.8	\$ 43.7	\$ 262.8	\$ 240.3	\$ (122.0)	\$ (43.0)	\$ (11.5)	\$ (67.5)	\$ (0.49)
As a % of reported net sales		37.5%	3.9%	23.2%		(10.8)%	(3.8)%	(1.0)%	(6.0)%	
Effective tax rate								14.5%		
<i>Adjustments:</i>										
Amortization expense related primarily to acquired intangible assets		\$ 52.5	\$ (0.3)	\$ (32.7)	\$ —	\$ 85.5	\$ —	\$ —	\$ 85.5	\$ 0.62
Impairment charges		—	—	—	(221.8)	221.8	—	—	221.8	1.61
Gain/loss on divestitures		—	—	3.6	—	(3.6)	(1.5)	—	(2.1)	(0.02)
Unusual litigation		—	—	(1.4)	—	1.4	—	—	1.4	0.01
Restructuring charges and other termination benefits		—	—	—	(18.0)	18.0	—	—	18.0	0.13
Change in financial assets		—	—	—	—	—	74.9	—	(74.9)	(0.54)
Acquisition-related charges and contingent consideration adjustments		—	—	(0.9)	(0.5)	1.4	—	—	1.4	0.01
Losses on investment securities		—	—	—	—	—	(1.0)	—	1.0	0.01
Separation and reorganization expense		—	—	(5.8)	—	5.8	—	—	5.8	0.04
Non-GAAP tax adjustments*		—	—	—	—	—	—	40.5	(40.5)	(0.29)
Adjusted		\$ 477.3	\$ 43.4	\$ 225.6	\$ —	\$ 208.3	\$ 29.4	\$ 29.0	\$ 149.9	\$ 1.09
As a % of reported net sales		42.1%	3.8%	19.9%		18.4%	2.6%	2.6%	13.2%	
Effective tax rate								16.2%		

Diluted weighted average shares outstanding

Reported **137.4**

Effect of dilution as reported amount was a loss, while adjusted amount was income** 0.5

Adjusted **137.9**

*The non-GAAP tax adjustments are due to tax effects of pretax non-GAAP adjustments that are calculated based upon the specific rate of the applicable jurisdiction of the pretax items.

**In the period of a net loss, diluted shares outstanding equal basic shares outstanding.



TABLE I (CONTINUED)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
SELECTED CONSOLIDATED INFORMATION
(in millions, except per share amounts)
(unaudited)

	Three Months Ended September 30, 2017										
	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Restructuring, Impairment Charges, and Other Operating Income	Operating Income	Interest, Other, and Change in financial assets	Income Tax Expense	Net Income	Diluted Earnings per Share	
Consolidated Reported	\$ 1,231.3	\$ 497.8	\$ 38.4	\$ 288.3	\$ 8.7	\$ 162.4	\$ 33.7	\$ 84.2	\$ 44.5	\$ 0.31	
As a % of reported net sales		40.4%	3.1%	23.4%		13.2%	2.7%	6.8%	3.6%		
Effective tax rate								65.5%			
<i>Adjustments:</i>											
Amortization expense primarily related to acquired intangible assets	\$ —	\$ 55.3	\$ (0.3)	\$ (34.5)	\$ —	\$ 90.1	\$ —	\$ —	\$ 90.1	\$ 0.63	
Change in financial assets	—	—	—	—	—	—	(2.6)	—	2.6	0.02	
Acquisition-related charges and contingent consideration adjustments	—	—	—	—	2.9	(2.9)	—	—	(2.9)	(0.02)	
Impairment charges	—	—	—	—	(7.8)	7.8	—	—	7.8	0.06	
Gain/loss on divestitures	—	—	—	—	—	—	1.9	—	(1.9)	(0.01)	
Operating results attributable to held-for-sale business*	(16.5)	(9.4)	(2.4)	(4.2)	—	(2.8)	1.3	—	(4.1)	(0.03)	
Restructuring charges and other termination benefits	—	—	—	—	(3.8)	3.8	—	—	3.8	0.03	
Non-GAAP tax adjustments**	—	—	—	—	—	—	—	(57.3)	57.3	0.40	
Adjusted	\$ 1,214.8	\$ 543.7	\$ 35.7	\$ 249.6	\$ —	\$ 258.4	\$ 34.3	\$ 26.9	\$ 197.2	\$ 1.39	
As a % of adjusted net sales		44.8%	2.9%	20.6%		21.3%	2.8%	2.2%	16.2%		
Effective tax rate								12.0%			
											Diluted weighted average shares outstanding
											Reported
											141.7

*Held-for-sale business includes the Israel API business.

**The non-GAAP tax adjustments include the following: (1) \$(23.2) million of tax effects of pretax non-GAAP adjustments that are calculated based upon the specific rate of the applicable jurisdiction of the pretax item; (2) a \$36.2 million effect on non-GAAP income taxes related to the interim tax accounting requirements within ASC 740, Income Taxes; (3) \$10.0 million net impact related to valuation allowances on deferred tax assets commensurate with non-GAAP pre-tax measures; (4) \$(5.4) million of tax adjustments related to the divestiture of the Tysabri® financial asset; (5) \$12.8 million related to an IRS audit settlement; and (6) \$26.9 million of tax related to the sale of our Israel API business.

TABLE I (CONTINUED)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
SELECTED CONSOLIDATED INFORMATION
(in millions, except per share amounts)
(unaudited)

Nine Months Ended September 29, 2018

Consolidated	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Restructuring, Impairment Charges, and Other Operating Income	Operating Income	Interest, Other, and Change in financial assets	Income Tax Expense	Net Income	Diluted Earnings per Share
Reported	\$ 3,536.5	\$ 1,388.5	\$ 174.0	\$ 832.2	\$ 253.3	\$ 129.0	\$ 42.1	\$ 37.3	\$ 49.6	\$ 0.36
As a % of reported net sales		39.3%	4.9%	23.5%		3.6%	1.2%	1.1%	1.4%	
Effective tax rate								43.0%		
<i>Adjustments:</i>										
Amortization expense related primarily to acquired intangible assets		\$ 159.3	\$ (0.7)	\$ (100.4)	\$ —	\$ 260.4	\$ —	\$ —	\$ 260.4	\$ 1.87
Acquisition-related charges and contingent consideration adjustments		—	(50.0)	(0.9)	(7.9)	58.8	—	—	58.8	0.42
Restructuring charges and other termination benefits		—	—	(4.0)	(23.2)	27.2	—	—	27.2	0.20
Gain/Loss on divestitures		—	—	3.5	1.3	(4.8)	(1.5)	—	(3.3)	(0.02)
Change in financial assets		—	—	—	—	—	65.9	—	(65.9)	(0.47)
Unusual litigation		—	—	(1.4)	—	1.4	—	—	1.4	0.01
Separation and reorganization expense		—	—	(5.8)	—	5.8	—	—	5.8	0.04
Impairment charges		—	—	—	(223.5)	223.5	—	—	223.5	1.61
Losses on investment securities		—	—	—	—	—	(11.6)	—	11.6	0.08
Non-GAAP tax adjustments*		—	—	—	—	—	—	72.0	(72.0)	(0.52)
Adjusted		\$ 1,547.8	\$ 123.3	\$ 723.2	\$ —	\$ 701.3	\$ 94.9	\$ 109.3	\$ 497.1	\$ 3.58
As a % of reported net sales		43.8%	3.5%	20.5%		19.8%	2.7%	3.1%	14.1%	
Effective tax rate								18.0%		

Diluted weighted average shares outstanding

Reported

139.0

*The non-GAAP tax adjustments include the following: (1) \$(81.9) million of tax effect related primarily to audit settlements and other discrete items; (2) \$(1.6) million of net impact related to tax rate changes on deferred tax assets; (3) \$7.7 million net impact related to valuation allowances on deferred tax assets commensurate with non-GAAP pre-tax measures; and (4) \$3.8 million of tax effects related to the accrual for non-current income taxes payable.



TABLE II
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
SELECTED SEGMENT INFORMATION

(in millions)
(unaudited)

	Three Months Ended September 29, 2018					Three Months Ended September 30, 2017				
	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income (Loss)	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income
Consumer Healthcare Americas										
Reported	\$ 596.2	\$ 184.7	\$ 13.8	\$ 72.9	\$ (123.9)	\$ 598.8	\$ 206.1	\$ 13.8	\$ 70.4	\$ 124.3
As a % of reported net sales		31.0%	2.3%	12.2%	(20.8)%		34.4%	2.3%	11.8%	20.8%
<i>Adjustments:</i>										
Amortization expense primarily related to acquired intangible assets		\$ 10.6		\$ (4.7)	\$ 15.3		\$ 12.1		\$ (4.8)	\$ 16.9
Impairment charges		—		—	221.8		—		—	0.5
Restructuring charges and other termination benefits		—		—	—		—		—	(0.8)
Acquisition-related charges and contingent consideration adjustments		—		—	—		—		—	(2.0)
Adjusted		\$ 195.3		\$ 68.2	\$ 113.2		\$ 218.2		\$ 65.6	\$ 138.9
As a % of reported net sales		32.7%		11.4%	19.0%		36.4%		10.9%	23.2%

	Three Months Ended September 29, 2018					Three Months Ended September 30, 2017				
	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income (Loss)	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income
Consumer Healthcare International										
Reported	\$ 357.6	\$ 166.7	\$ 10.7	\$ 140.4	\$ (2.0)	\$ 365.4	\$ 165.9	\$ 10.5	\$ 147.1	\$ 4.6
As a % of reported net sales		46.6%	3.0%	39.2%	(0.6)%		45.4%	2.9%	40.3%	1.2%
<i>Adjustments:</i>										
Amortization expense primarily related to acquired intangible assets		\$ 21.5	\$ (0.3)	\$ (27.9)	\$ 49.7		\$ 21.9	\$ (0.3)	\$ (29.6)	\$ 51.8
Restructuring charges and other termination benefits		—	—	—	18.0		—	—	—	3.6
Unusual litigation		—	—	(1.4)	1.4		—	—	—	—
Acquisition-related charges and contingent consideration adjustments		—	—	—	(0.3)		—	—	—	—
Adjusted		\$ 188.2	\$ 10.4	\$ 111.1	\$ 66.8		\$ 187.8	\$ 10.2	\$ 117.5	\$ 60.0
As a % of reported net sales		52.6%	2.9%	31.1%	18.7%		51.4%	2.8%	32.2%	16.4%

TABLE II (CONTINUED)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
SELECTED SEGMENT INFORMATION
(in millions)
(unaudited)

	Three Months Ended September 29, 2018					Three Months Ended September 30, 2017				
	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income
Prescription Pharmaceuticals										
Reported	\$ 179.3	\$ 73.4	\$ 19.2	\$ 17.4	\$ 36.0	\$ 250.6	\$ 116.7	\$ 12.2	\$ 19.2	\$ 82.1
As a % of reported net sales		41.0%	10.7%	9.7%	20.1%		46.6%	4.9%	7.7%	32.8%
<i>Adjustments:</i>										
Amortization expense primarily related to acquired intangible assets		\$ 20.4		\$ (0.1)	\$ 20.5		\$ 20.9		\$ (0.1)	\$ 21.0
Restructuring charges and other termination benefits		—		—	—		—		—	0.1
Impairment charges		—		—	—		—		—	4.0
Acquisition-related charges and contingent consideration adjustments		—		—	0.8		—		—	(0.9)
Adjusted		\$ 93.8		\$ 17.3	\$ 57.3		\$ 137.6		\$ 19.1	\$ 106.3
As a % of reported net sales		52.3%		9.6%	31.9%		54.9%		7.6%	42.4%

TABLE II (CONTINUED)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
SELECTED SEGMENT INFORMATION
(in millions)
(unaudited)

	Nine Months Ended September 29, 2018					Nine Months Ended September 30, 2017				
	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income (Loss)	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income
Consumer Healthcare International										
Reported	\$ 1,140.0	\$ 542.4	\$ 32.9	\$ 471.2	\$ 18.4	\$ 1,116.8	\$ 509.4	\$ 31.3	\$ 450.8	\$ 8.7
As a % of reported net sales		47.6%	2.9%	41.3%	1.6%		45.6%	2.8%	40.4%	0.8%
<i>Adjustments:</i>										
Amortization expense primarily related to acquired intangible assets		\$ 66.4	\$ (0.7)	\$ (86.0)	\$ 153.1		\$ 62.8	\$ (0.9)	\$ (83.8)	\$ 147.5
Impairment charges		—	—	—	1.1		—	—	—	4.8
Restructuring charges and other termination benefits		—	—	—	19.1		—	—	—	13.2
Unusual litigation		—	—	(1.4)	1.4		—	—	8.8	(8.8)
Operating results attributable to held-for-sale business*		—	—	—	—		0.5	—	—	0.5
Acquisition-related charges and contingent consideration adjustments		—	—	—	(0.3)		—	—	—	0.6
Adjusted		\$ 608.8	\$ 32.2	\$ 383.8	\$ 192.8		\$ 572.7	\$ 30.4	\$ 375.8	\$ 166.5
As a % of reported net sales		53.4%	2.8%	33.7%	16.9%		51.3%	2.7%	33.7%	14.9%

* Held-for-sale business includes the European sports brand.

TABLE III
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
CONSTANT CURRENCY
(in millions)

	Three Months Ended		Total Change	FX Change	Constant Currency Change
	September 29, 2018	September 30, 2017			
Net sales					
Consolidated*	\$ 1,133.1	\$ 1,214.8	(6.7)%	1.0%	(5.7)%
CHCA	\$ 596.2	\$ 598.8	(0.4)%	0.3%	(0.1)%
CHCI	\$ 357.6	\$ 365.4	(2.1)%	2.7%	0.6%
RX	\$ 179.3	\$ 250.6	(28.5)%	—%	(28.5)%
CHCA	\$ 596.2	\$ 598.8			
Less: Animal health net sales	(20.4)	(39.2)			
	<u>\$ 575.8</u>	<u>\$ 559.6</u>	2.9%	0.3%	3.2%
CHCI	\$ 357.6	\$ 365.4			
Less: Belgium distribution and Russian business net sales	—	(1.8)			
	<u>\$ 357.6</u>	<u>\$ 363.6</u>	(1.7)%	2.8%	1.1%
CHCA	\$ 596.2	\$ 598.8			
CHCI	357.6	365.4			
Less: Belgium distribution and Russian business net sales	—	(1.8)			
Less: Animal health net sales	(20.4)	(39.2)			
	<u>\$ 933.4</u>	<u>\$ 923.2</u>	1.1%	1.3%	2.4%
	Nine Months Ended		Total Change	FX Change	Constant Currency Change
	September 29, 2018	September 30, 2017			
CHCA	\$ 1,794.6	\$ 1,786.4			
Less: Animal health net sales	(78.6)	(112.8)			
	<u>\$ 1,716.0</u>	<u>\$ 1,673.6</u>	2.5%	0.1%	2.6%

*2017 net sales are adjusted to exclude sales attributable to divested businesses. See Table I for non-GAAP reconciliations.



TABLE IV
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP
MEASURES
2018 CONSOLIDATED GUIDANCE⁽¹⁾
(unaudited)

	Full Year 2018 EPS Guidance Provided on 11/8/2018
Reported⁽²⁾	\$0.66 - \$0.86
Amortization expense related primarily to acquired intangible assets	2.44
Impairment charges	1.61
Acquisition-related charges and contingent consideration adjustments	0.42
Restructuring charges and other termination benefits	0.20
Separation and reorganization expense	0.13
Losses on investment securities	0.08
Unusual litigation	0.01
Gain/loss on divestitures	(0.02)
Change in financial assets	(0.47)
Tax effect of non-GAAP adjustments	(0.61)
Adjusted	\$4.45 - \$4.65

	Full Year 2018 Guidance Provided on 11/8/2018
Consolidated Operating Income	
Reported	Approx. \$227 - \$257 million
Amortization expense related primarily to acquired intangible assets	339
Impairment charges	223
Acquisition and integration-related charges and contingent consideration adjustments	59
Restructuring charges and other termination benefits	27
Operational separation	19
Unusual litigation	1
Gain/loss on divestitures	(5)
Adjusted	Approx. \$890 - \$920 million

(1) Guidance tables include Q1-Q3 actual results for all reconciling line items, plus estimated amortization expense, separation and reorganization expense and the corresponding tax effect for Q4.

(2) Guidance excludes any impact related to the Royalty Pharma contingent milestone payments.



TABLE IV (CONTINUED)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP
MEASURES
2018 CONSOLIDATED GUIDANCE⁽¹⁾
(unaudited)

	Full Year 2018 EPS Guidance Provided on 8/9/2018
Reported⁽²⁾	\$2.11 - \$2.31
Amortization expense related primarily to acquired intangible assets	2.48
Acquisition-related charges and contingent consideration adjustments	0.41
Losses on investment securities	0.08
Restructuring charges and other termination benefits	0.07
Change in financial assets	0.06
Impairment charges	0.01
Gain on divestitures	(0.01)
Tax effect of non-GAAP adjustments	(0.46)
Adjusted	\$4.75 - \$4.95

	Full Year 2018 Guidance provided on 5/8/2018
Consolidated Operating Income	
Reported	Approx. \$669 - \$729 million
Amortization expense related primarily to acquired intangible assets	352
Restructuring charges and other termination benefits, acquisition-related charges and contingent consideration adjustments	10
Gain on divestitures	(1)
Adjusted	Approx. \$1,030 - \$1,090 million

⁽¹⁾ Guidance tables include Q1-Q2 actual results for all reconciling line items, plus estimated amortization expense and the corresponding tax effect for Q3-Q4.

⁽²⁾ Guidance excludes any impact related to the Royalty Pharma contingent milestone payments.

TABLE IV (CONTINUED)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
2018 SEGMENT GUIDANCE⁽¹⁾
(unaudited)

	Full Year 2018 Guidance Provided on 11/8/2018
	Operating margin
CHCA⁽²⁾	
Reported	Approx. 6.5%
Impairment charges	9.2%
Amortization expense related to acquired intangible assets	2.3%
Acquisition and integration-related charges and contingent consideration adjustments	2.0%
Adjusted	Approx. 20.0%
CHCI⁽²⁾	
Reported	Approx. 1.6%
Amortization expense related primarily to acquired intangible assets	13.4%
Restructuring charges and other termination benefits	1.3%
Impairment charges	0.1%
Unusual litigation	0.1%
Adjusted	Approx. 16.5%
RX⁽³⁾	
Reported	Approx. 24.7% - 27.7%
Amortization expense related to acquired intangible assets	10.3%
Acquisition and integration-related charges and contingent consideration adjustments	1.2%
Gain on divestitures	(0.2)%
Adjusted	Approx. 36.0 - 39.0%

⁽¹⁾ Guidance tables include Q1-Q3 actual results for all reconciling line items, plus estimated amortization expense, separation and reorganization expense and the corresponding tax effect for Q4.

⁽²⁾ Expected to be within +/- 100 basis points.

⁽³⁾ Expected to be within +/- 200 basis points.

TABLE IV (CONTINUED)
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP
MEASURES
2018 CONSOLIDATED GUIDANCE⁽¹⁾
(unaudited)

	Full Year Modeling Estimates		
Consolidated DSG&A as a % of Net Sales			
Reported	Approx. 23.2%		
Gain/loss on divestitures	0.1%		
Restructuring and other termination benefits	(0.1)%		
Operational separation	(0.4)%		
Amortization expense related primarily to acquired intangible assets	(2.8)%		
Adjusted	Approx. 20.0%		
Consolidated R&D as a % of Net Sales			
Reported	Approx. 5.1%		
Acquisition and integration-related charges and contingent consideration adjustments	(1.1)%		
Adjusted	Approx. 4.0%		
Interest and other expense	Approx. \$130 million		
Effective Tax Rate	Tax expense (in millions)	Pre-tax income (in millions)	Effective Tax Rate
Reported	\$ 62	\$ 163	Approx. 38.0%
Non-GAAP adjustments	85	611	
Adjusted	\$ 147	\$ 774	Approx. 19.0%
Diluted shares outstanding	Approx. 138.5 million		
Adjusted operating cash flow			
Reported	\$ 550.0		
Less: IPR&D Investments	50.0		
Adjusted	\$ 600.0		

⁽¹⁾ Guidance tables include Q1-Q3 actual results for all reconciling line items, plus estimated amortization expense, separation and reorganization expense and the corresponding tax effect for Q4.

TABLE V
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP
MEASURES
(in millions)
(unaudited)

	Three months ended		
	March 31, 2018	June 30, 2018	September 29, 2018
CHCI advertising and promotional spend	\$ 52.0	\$ 48.5	\$ 35.1
Consolidated depreciation expense	\$ 22.3	\$ 23.1	\$ 21.8
	Three Months Ended	Nine Months Ended	
	September 29, 2018	September 29, 2018	
Operating cash flow	\$ 144.0	\$ 398.7	
Less: IPR&D Investments	—	50.0	
Adjusted operating cash flow	\$ 144.0	\$ 448.7	
Adjusted net income	\$ 149.9	\$ 497.1	
Cash conversion ratio	96%	90%	

